Shenzhen Taili Biomedicine Co., Ltd.

Primary objective: According to the relevant provisions of bioequivalence tests, brepirazole tablets (RXULTI®, specification: 2 mg) of Otsuka Pharmaceutical Netherlands B.V. were selected as the reference preparation. The test preparation brepirazole orodispersible film (specification: 2 mg) provided by Shenzhen Yujian Biopharmaceutical Co., Ltd. was subjected to human bioequivalence tests under fasting and postprandial administration conditions, and the pharmacokinetic characteristics of the test preparation and the reference preparation were compared to evaluate the bioequivalence of the two preparations under fasting or postprandial administration conditions. Secondary objectives: To evaluate the palatability (including taste, odor, aftertaste), grittiness, adhesion and irritation of brepirazole orodispersible film; to evaluate the safety of single-dose oral administration of the test preparation brepirazole orodispersible film (specification: 2 mg) and the reference preparation brepirazole tablets (specification: 2 mg) in healthy Chinese subjects.

(1) To evaluate the effect of a high-fat diet on the pharmacokinetic response of a single oral administration of NF2105 capsules to healthy subjects; (2) To evaluate the effect of NF2105 capsules (before or after meals) and nilotinib (400 mg) capsules on the QT/QTc interval after fasting administration to healthy Chinese subjects; (3) To preliminarily evaluate the relative bioavailability of NF2105 capsules and nilotinib capsules after a single oral administration to healthy subjects on an empty stomach; (4) To evaluate the PK characteristics and PK/PD (QT/QTc interval) of a single oral administration of NF2105 capsules (fasting or after meals) and nilotinib capsules (fasting) to healthy subjects; (5) To evaluate the safety of oral administration of NF2105 capsules or nilotinib capsules to healthy subjects.

Primary objective: To investigate the PK characteristics and dose-proportion relationship of NF2105 in healthy subjects after single oral administration of different doses on an empty stomach; To compare the PK characteristics of NF2105 and nilotinib capsules in healthy subjects after single oral administration on an empty stomach, and to explore the doses with similar exposure levels. Secondary objective: To evaluate the safety and tolerability of NF2105 in healthy subjects after single oral administration of different doses on an empty stomach; To evaluate the effects of NF2105 and nilotinib capsules on the QT/QTc interval in healthy subjects.